2023 Fiscal Year Final Research Report
Validation of apolipoproteinB-100,serum paraoxonase-1,cell-free DNA as a biomarker for mesenteric ischemia
| Project/Area Number |
21K09011
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55060:Emergency medicine-related
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中田 孝明 千葉大学, 大学院医学研究院, 教授 (20375794)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | Cell-free DNA / Proteomics / ApolipoproteinB-100 / Serum paraoxonase-1 |
|---|
| Outline of Final Research Achievements |
A paper on an animal model of intestinal ischaemia with cell-free DNA, which was in the process of submission, has been accepted (J Surg Res. 2022 Jan:269:28-35.). The quantitative testing of the two proteins (ApolipoproteinB-100/Serum paraoxonase-1) in animal models has not yet been performed in sufficient number of experiments and will be carried out in the future. The validation of the three biomarkers ApolipoproteinB-100/Serum paraoxonase-1 (PON-1)/Cell-free DNA in human clinical specimens is specimen-intensive and progressing well.
|
| Free Research Field |
救急集中治療医学
|
| Academic Significance and Societal Importance of the Research Achievements |
腸間膜虚血は早期診断が困難かつ致死的な疾患であり、早期診断方法、biomarkerの開発は同疾患の救命率向上に貢献する．Proteomicsを用いて導出した新規biomarkerの探索は、他の疾患にも応用できる可能性があり、発展性がある．
|
